SCHEMBL607150

SCHEMBL607150

CCOC1CCC(N2CCC(c3c(F)ccc(N)c3N)CC2)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 2/20 0.39
CHRM4 P08173 5/20 0.32
CHRM1 P11229 5/20 0.32
CHRM5 P08912 4/20 0.32
CHRM2 P08172 3/20 0.32
CHRM3 P20309 3/20 0.32
HCRTR2 O43614 6/20 0.32
DRD2 P14416 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1A P35348 1/20 0.32
ADRA1B P35368 1/20 0.32
PARP1 P09874 2/20 0.31
DPP4 P27487 1/20 0.31
DPP8 Q6V1X1 1/20 0.31
DPP9 Q86TI2 1/20 0.31
DPP7 Q9UHL4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607149 1.00 ABCB1 (0.39) ABCB1CHRM4CHRM1CHRM5CHRM2
SCHEMBL605592 0.84 ABCB1 (0.44) ABCB1CHRM4CHRM1CHRM5CHRM2
SCHEMBL605591 0.84 ABCB1 (0.44) ABCB1CHRM4CHRM1CHRM5CHRM2
SCHEMBL604342 0.78 CHRM4 (0.38) ABCB1CHRM4CHRM1CHRM2DRD2
SCHEMBL604341 0.78 CHRM4 (0.38) ABCB1CHRM4CHRM1CHRM2DRD2
SCHEMBL605668 0.76 HCRTR2 (0.32) ABCB1CHRM1CHRM2HCRTR2
SCHEMBL604604 0.76 HCRTR2 (0.32) ABCB1CHRM1CHRM2HCRTR2
SCHEMBL604603 0.76 HCRTR2 (0.32) ABCB1CHRM1CHRM2HCRTR2
SCHEMBL459226 0.72 ABCB1 (0.36) ABCB1
SCHEMBL10203529 0.71 MAPK8 (0.37) DRD2ADRA1DADRA1AADRA1BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004182-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-08 EP disclosed
US-20120316202-A1 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED 2012-12-13 US disclosed
US-20120041028-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED 2012-02-16 US disclosed
US-20100280071-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2010-11-04 US disclosed
EP-2004182-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-24 EP disclosed
WO-2007107565-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041028-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 ABCB1 823/4885CHRM4 3/4885CHRM1 1/4885
US-20100280071-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 ABCB1 823/4885CHRM4 3/4885CHRM1 1/4885
US-20120316202-A1 Compounds which have activity at M1 receptor and their uses in medicine CHRM1, CHRM2, CHRM5 ABCB1 755/4885CHRM4 4/4885CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.